← back to search

Zhendong Zheng

Harbin Institute of Technology · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Immune Cell Function and Interaction, and Colorectal Cancer Treatments and Studies.
h-index
23
citations
1,849
works
111
NIH funding
primary concept
Medicine
email

Recent publications

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Nature Medicine 2025cited by 76position: middledoi
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Nature Medicine 2025cited by 2position: middledoi
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
European journal of medical research 2025cited by 0position: middledoi
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Hematological Oncology 2022cited by 9position: middledoi
Combination of donafenib and anti-PD-1 antibody plus trans-arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology 2022cited by 5position: middledoi
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Journal of Clinical Oncology 2021cited by 404position: middledoi
Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study
Blood 2021cited by 1position: middledoi
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study
Lung Cancer 2020cited by 21position: middledoi
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
The Lancet Respiratory Medicine 2019cited by 136position: middledoi
High-Throughput Phosphotyrosine Protein Complexes Screening by Photoaffinity-Engineered Protein Scaffold-Based Forward-Phase Protein Array
Analytical Chemistry 2019cited by 7position: firstdoi
The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: An interim analysis of a multicenter, phase II trial.
Journal of Clinical Oncology 2019cited by 0position: middledoi
Real‐world <i>EGFR</i> testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
Thoracic Cancer 2018cited by 36position: middledoi
A multi-center survey on dietary knowledge and behavior among inpatients in oncology department
Supportive Care in Cancer 2018cited by 26position: middledoi
Ag<sub>2</sub>O/sodium alginate supramolecular hydrogel as a film photocatalyst for removal of organic dyes in wastewater
RSC Advances 2017cited by 26position: middledoi
Effects of health education intervention on negative emotion and quality of life of patients with laryngeal cancer after postoperative radiotherapy
Cancer/Radiothérapie 2017cited by 20position: middledoi
JCES 01.11 A Multicenter, Non-Interventional Study on Real World EGFR Testing and in Patients with IIIB/IV NSCLC in Northern China
Journal of Thoracic Oncology 2017cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shun Feng · Xinjiang University2 papers (2017–2019)Bizhu Chu · Guangzhou University of Chinese Medicine1 papers (2019–2019)Yu Fang · Sun Yat-sen University Cancer Center1 papers (2018–2018)Mi Ke · Jiangsu University1 papers (2019–2019)Yan qiao Zhang · Harbin Medical University1 papers (2019–2019)Yuhua Ma · Xinjiang University1 papers (2017–2017) · 1 papers (2019–2019)Jun Han · Inner Mongolia Agricultural University1 papers (2017–2017)Juan Du · Xinjiang University1 papers (2017–2017)Hanping Shi · Capital Medical University1 papers (2018–2018)Ruijun Tian · Southern University of Science and Technology1 papers (2019–2019)Yong Liu · Jilin University1 papers (2018–2018)Jing Shi · Singapore Institute of Technology1 papers (2019–2019)Shanzhi Gu · Harbin Medical University1 papers (2022–2022)Lingjun Zhu · Jilin University1 papers (2018–2018)Yi Lu · Xinjiang University1 papers (2019–2019)Tongsen Zheng · Harbin Medical University1 papers (2022–2022)Yuee Teng · Henan Academy of Agricultural Sciences1 papers (2019–2019)Jiang Zhu · Nantong University1 papers (2018–2018)Quanfu Li · Shanghai Medical College of Fudan University1 papers (2018–2018)